PRKCE

Across TCGA pan-cancer cohorts, PRKCE mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRKCE data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PRKCE mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PRKCE expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, LUAD, and GBM are the cancer types where PRKCE mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.951	0.343	.005	18	view →
LUAD	DFS	Quartile	II,III,IV	0.258	0.778	.003	8	view →
GBM	DFS	Tertile	All	0.881	0.700	.006	6	view →
HNSC	DFS	Median	IV	0.905	1.000	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRKCE–PDAC (OS)

Open the PDAC breakdown →